Krystal has begun first patient dosing of KYANITE-1 (P-I) study of Inhaled KB707 monotherapy in an open label trial to treat LA/M solid tumors of the lung.
Krystal Biotech received two US FDA FTDs for KB707 program: intratumoral use for anti-PD-1 r/r melanoma in Jul 2023 and inhaled use for solid tumors with pulmonary metastases in Feb 2024
Inhaled KB707 is a modified HSV-1 vector designed to enter into the lung and deliver genes encoding both human IL-12 and IL-2. Krystal Biotech is expecting readout data in later 2024
Ref: Krystal Biotech | Image: Krystal Biotech
Related News:- Krystal Biotech Reports EMA’s Validation of Vyjuvek for MAA to Treat Dystrophic Epidermolysis Bullosa (DEB)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
